Skip to content

Sleep Quality in Mechanically Ventilated Patients

The Influence of Mode and Patient-ventilator Interaction on Sleep Quality in the ICU

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01410149
Enrollment
13
Registered
2011-08-04
Start date
2007-04-30
Completion date
2011-12-31
Last updated
2012-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Failure

Keywords

PAV (proportional assist ventilation); sleep; polysomnography; mechanical ventilation

Brief summary

Patients requiring mechanical ventilation in the ICU will undergo three consecutive nights of polysomnography to record sleep patterns while receiving three modes of mechanical ventilation; Proportional assist ventilation (PAV), Pressure support ventilation (PSV), Assist control ventilation (ACV), applied in random order. The purpose is to determine the effect of mode of mechanical ventilation on patient-ventilator asynchrony and sleep quality.

Interventions

OTHERPAV

Proportional Assist Ventilation will be used to ventilate the patient for a 24 hour period

OTHERPSV

Pressure Support Ventilation will be used to ventilate the patient for a 24 hour period

OTHERACV

Assist Control Ventilation will be used to ventilate the patient for a 24 hour period

Sponsors

Ontario Lung Association
CollaboratorOTHER
Medtronic - MITG
CollaboratorINDUSTRY
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-75 * received mechanical ventilation \>72 hours * glasgow coma scale \>10 * acute physiology score \<13 * ready for partial ventilatory support: intact respiratory drive, PaO2/FiO2 ratio \>200 on positive end expiratory pressure (PEEP) less than or equal to 5 cmH2O, and PH of 7.35 to 7.45 * sedation: analgesia at dose not higher than 0.01 mg/kg/hr morphine equivalent x 48 hours, sedation at dose not higher than 0.01 mg/kg/hr lorazepam equivalent x 72 hours. * anticipate ongoing need for partial ventilatory support for the following 72 hours

Exclusion criteria

* Successful completion of spontaneous breathing trial * Neurological injury, encephalopathy or abnormal EEG * History of central sleep apnea * General anaesthesia within 72 hours from study entry * Requiring haloperidol \>10 mg/24 hours * hemodynamically unstable * sepsis

Design outcomes

Primary

MeasureTime frameDescription
Sleep quality3 nightsSleep fragmentation (number of arousals and awakenings/hr sleep), sleep architecture (% time asleep spent in Stage 1, 2, 3/4 and REM sleep)

Secondary

MeasureTime frameDescription
Patient-ventilator asynchrony3 nightsIncidence of patient-ventilator asynchrony (asynchrony index, % of asynchronous breaths per minute)

Other

MeasureTime frameDescription
Delirium3 daysPositive score on a delirium screening tool (CAM-ICU or ICDSC)
Comfort3 daysPatient's assessment of their own breathing comfort and their perceived quality of sleep, indicated on a visual analogue scale
Respiratory pattern3 nightsMeasurement of average tidal volume, respiratory rate, minute ventilation and non-invasive measurement of respiratory muscle effort relative to maximum effort
Blood gasevening and morningmeasurement of paO2 and paCO2

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026